基于分子分型的高中危子宫内膜癌辅助治疗:PORTEC-4a 随机三期非劣效试验结果
PORTEC-4a 是一项在 8 个欧洲国家开展的随机、开放标签、三期、多中心非劣效试验,纳入早期高中危子宫内膜癌患者,术后按 2:1 随机分配至分子整合风险分型指导的个体化辅助治疗组或标准阴道近距离放疗组。
要点
- 分子整合风险分型指导的辅助治疗在高中危子宫内膜癌中非劣效于标准阴道近距离放疗。
- 46% 有利分型患者得以免除辅助治疗,减少了过度治疗与治疗不足。
- 3 级及以上治疗相关泌尿生殖毒性两组相似(1% vs 2%),未发生治疗相关死亡。
核心结论
- 基于分子整合风险分型的个体化辅助治疗对高中危子宫内膜癌患者安全有效,可使 46% 有利分型患者免除辅助治疗,并减少过度治疗和治疗不足。
研究设计与样本
- PORTEC-4a 为随机、开放标签、三期、多中心非劣效试验,在 8 个欧洲国家开展。
- 纳入年龄≥18 岁、WHO 体力状态评分 0-2 的早期高中危子宫内膜癌患者,术后按 2:1 随机分配至分子分型指导组或标准阴道近距离放疗组。
- 主要终点为阴道复发作为首次事件的 5 年累积发生率,在意向治疗人群中分析。
主要发现
- 分子分型组中 168 例(46%)为有利分型,148 例(40%)为中间分型,51 例(14%)为不利分型。
- 不良事件主要为 1-2 级,3 级及以上治疗相关泌尿生殖毒性在分子分型组为 4/367(1%),标准组为 4/197(2%);发生 5 例严重不良事件,其中 1 例可能与治疗相关(阴道瘢痕裂开),无治疗相关死亡。
关键数值与推荐
- 有利分型(POLE 突变或无特定分子分型[NSMP]-CTNNB1 野生型)接受观察。
- 中间分型(错配修复缺陷或 NSMP-CTNNB1 突变)接受阴道近距离放疗(21 Gy,分 3 次,每次 7 Gy,间隔 5-7 天)。
临床怎么用
- 对高中危子宫内膜癌术后患者,可依据分子整合风险分型选择观察、阴道近距离放疗或盆腔放疗,以避免过度治疗和治疗不足。
- 有利分型患者可考虑免除辅助治疗,但需告知其阴道复发风险略高于标准阴道近距离放疗。
局限性
- 原文未报告种族和民族数据。
- 随访仍在进行中,当前报告为 5 年累积发生率结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control. METHODS: PORTEC-4a was a randomised, open-label, phase 3, multicentre, non-inferiority trial, conducted across eight European countries. Women (aged ≥18 years and with a WHO performance score of 0-2) with early stage high-intermediate risk endometrial cancer were eligible. Patients were randomly assigned post-surgery in a 2:1 ratio to either adjuvant treatment according to their molecular integrated risk profile or to standard vaginal brachytherapy. Allocation used a biased-coin minimisation with stratification for participating centre, grade, and lymphadenectomy. Adjuvant treatment in the molecular-profile group in case of favourable profile (POLE-mutated or no specific molecular profile [NSMP]-CTNNB1 wildtype) was observation, for intermediate profile (mismatch repair deficient or NSMP-CTNNB1 mutated) was brachytherapy (21 Gy in three fractions of 7 Gy given at 5 to 7 day intervals), and for unfavourable profile (p53 abnormal or substantial lymphovascular space invasion or L1 cell adhesion molecule overexpression) was pelvic radiotherapy (45·0-48·6 Gy in 1·8-2·0 Gy fractions, 5 days per week). The primary endpoint was overall 5-year cumulative incidence of vaginal recurrence as first event. Kaplan-Meier, Cox model, and cumulative incidence with competing risks were used for final analysis in the intention-to-treat population. Patient advocates were involved during grant application and trial conduct. The trial is registered with the Netherlands Trial Registry (NTR5841), the ISRCTN registry (ISRCTN11659025), and ClinicalTrials.gov (NCT03469674), and follow-up is ongoing. FINDINGS: Between June 1, 2016, and Dec 24, 2021, 569 patients were enrolled in PORTEC-4a. After the addition of 23 favourable patients out of PORTEC-4, the final combined PORTEC-4a cohort consisted of 564 eligible and evaluable patients (367 in the molecular profile group and 197 in the standard group). All patients were female, the median age was 69·0 years (IQR 63·0-73·5), and data on race and ethnicity were not collected. Median follow-up was 58·1 months (IQR 40·7-63·6). In the molecular profile group 168 (46%) patients had a favourable profile, 148 (40%) had an intermediate profile, and 51 (14%) had an unfavourable profile. The 5-year cumulative incidence of vaginal recurrence was 4·5% (95% CI 2·23-6·76) in the molecular profile group and 1·6% (0·00-3·32) in the standard group (HR 2·71 [95% CI 0·79-9·34]). The upper-bound of the one-sided confidence interval of the difference (5·3%) was below the predefined-equivalence margin of 7·0% (pnon-inferiority=0·005). The second primary analysis in patients with a favourable molecular profile showed 5-year vaginal recurrence of 4·1% (95% CI 0·81-7·37) in the molecular profile group versus 0·9% (0·00-2·78) in the standard group (HR 3·97 [95% CI 0·48-32·95]). Adverse events were mainly grades 1-2, with grade 3 or above related genitourinary toxicities in four (1%) of 367 versus four (2%) of 197, without substantial differences between groups. Five serious adverse events occurred, of which one was possibly related to treatment (vaginal scar dehiscence). No treatment-related deaths occurred. INTERPRETATION: Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment. FUNDING: KWF Dutch Cancer Society.
引用
- van den Heerik ASVM, Horeweg N, Haverkort MAD, et al. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2026. PMID: 41449145. doi:10.1016/S1470-2045(25)00612-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。